Bayer : Moderate reduction in our earnings model - speculation about a spin-off was fuelled during the CC
>New FY 2023 earnings estimates are slightly below the company’s guidance - After we cut our estimates in the Crop Science division already, when the company warned on its FY 2023 earnings on 24 July, we are now fine-tuning our earnings model by reducing our estimates again predominantly in the Crop Science division. However, also in the Pharma division, we are slightly revising our adj. EBITDA projections by -1.1%, after we already reduced our estimates against the b...Bayer is a life sciences group based in Germany. Co.'s operations are organized along three divisions: Pharmaceuticals (engaged in prescription pharmaceuticals for cardiology and women's healthcare); Consumer Health (engaged in non-prescription products in dermatology, dietary supplement, analgesic, gastrointestinal, allergy, cold and flu, foot care, sun protection and cardiovascular risk prevention categories); and CropScience (engaged in the development of seeds and plant traits; crop protection; and for gardens, the green industry and non-agricultural pest control). Co. also maintains an Animal Health business unit engaged in the development of products for farm and companion animals.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.